Details for New Drug Application (NDA): 061764
✉ Email this page to a colleague
NDA 061764 describes VELOSEF, which is a drug marketed by Apothecon, Bristol Myers Squibb, and Ersana, and is included in five NDAs. Additional details are available on the VELOSEF profile page.
The generic ingredient in VELOSEF is cephradine. There are ten drug master file entries for this compound. Additional details are available on the cephradine profile page.
The generic ingredient in VELOSEF is cephradine. There are ten drug master file entries for this compound. Additional details are available on the cephradine profile page.
Summary for 061764
| Tradename: | VELOSEF |
| Applicant: | Apothecon |
| Ingredient: | cephradine |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 061764
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 250MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 500MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
